HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
K1jYPKB0FH8CwSmw